Citric acid

QWIN Launches a New THC-A Vape Pens and Flower Collection and a Tropical Fruits Delta 9 Syrup

Retrieved on: 
Monday, May 22, 2023

Westminster, California, May 22, 2023 (GLOBE NEWSWIRE) -- QWIN, a leading provider of high-quality hemp-derived products, has launched its new THC-A collection featuring vape pens and flower strains, as well as the latest Delta 9 syrup flavor in Tropic Punch.

Key Points: 
  • Westminster, California, May 22, 2023 (GLOBE NEWSWIRE) -- QWIN, a leading provider of high-quality hemp-derived products, has launched its new THC-A collection featuring vape pens and flower strains, as well as the latest Delta 9 syrup flavor in Tropic Punch.
  • This sweet and tangy formula is the most recent addition to QWIN’s top-selling Delta 9 syrup line featuring Strawmango, Berry Delight, and Georgia Peach.
  • In addition to QWIN’s new syrup flavor, the brand’s premier THC-A collection is powerful, hemp-based, and Farm Bill compliant.
  • “We are excited to introduce our new THC-A vape pens and flower strains, as well as our Delta 9 syrup in Tropic Punch flavor,” said QWIN founder Phiton Nguyen.

Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, April 28, 2023

SAN DIEGO, April 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), has reported financial results for the year ended December 31, 2022.

Key Points: 
  • Appointed Ivy Zhang as Chief Financial Officer and Secretary effective April 13, 2023.
  • "In 2022, we more than doubled Phexxi revenue while cutting costs 42%.
  • For the year ended December 31, 2022, net product sales were $16.8 million compared to $8.2 million in net product sales in the prior year.
  • We decreased selling and marketing costs by 61% to $44.0 million in 2022, compared to $113.2 million in the prior year.

Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary

Retrieved on: 
Friday, April 14, 2023

SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023.

Key Points: 
  • SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023.
  • Reporting to Chief Executive Officer Saundra Pelletier, Ms. Zhang will lead Evofem's finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions.
  • "We are delighted to welcome Ivy back to Evofem as our chief financial officer and secretary.
  • Ms. Zhang is a seasoned finance executive with more than 14 years of financial and accounting experience spanning diverse industries, including pharmaceuticals and medical devices.

Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required

Retrieved on: 
Wednesday, April 12, 2023

SAN DIEGO, April 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced a major new win in New York state that improves coverage for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free contraceptive vaginal gel, for more than 5.8 million lives statewide.

Key Points: 
  • SAN DIEGO, April 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced a major new win in New York state that improves coverage for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free contraceptive vaginal gel, for more than 5.8 million lives statewide.
  • New York Medicaid transitioned to a single Preferred Drug List effective April 1, 2023, that includes no Prior Authorization requirement on Phexxi.
  • This facilitates access to Phexxi for women covered by New York Medicaid, the largest of all Commercial and Medicaid payers in New York.
  • In the first quarter of 2023, Evofem gained Phexxi coverage for 16.3 million new lives from payers including Mississippi Medicaid, Indiana State Medicaid, multiple Blue Cross Blue Shield plans, and the largest commercial payer in Michigan.

Noble Biomaterials Ionic+® Botanical Technology Receives EPA Registration

Retrieved on: 
Thursday, March 23, 2023

SCRANTON, Pa., March 23, 2023 /PRNewswire/ -- Noble Biomaterials, a global leader in antimicrobial solutions for soft surface applications, announced its latest antimicrobial technology has received official EPA registration.

Key Points: 
  • SCRANTON, Pa., March 23, 2023 /PRNewswire/ -- Noble Biomaterials, a global leader in antimicrobial solutions for soft surface applications, announced its latest antimicrobial technology has received official EPA registration.
  • Noble Biomaterials began development of the proprietary Ionic+® Botanical formula in 2021 and filed for EPA registration as part of the development process.
  • "Sometimes innovative solutions are staring you right in the face," said Joel Furey, founder and chief commercial officer at Noble Biomaterials.
  • Receiving an EPA registration is a big step in the process of advancing Noble's Ionic+ Botanical products.

Feed Acidifiers Global Market Report 2023

Retrieved on: 
Monday, March 13, 2023

The global feed acidifiers market grew from $2.48 billion in 2022 to $2.71 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%.

Key Points: 
  • The global feed acidifiers market grew from $2.48 billion in 2022 to $2.71 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%.
  • The countries covered in the feed acidifiers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
  • The feed acidifiers market research report is one of a series of new reports that provides feed acidifiers market statistics, including global feed acidifiers industry size, regional shares, competitors with a feed acidifiers market share, detailed feed acidifiers market segments, market trends and opportunities, and any further data you may need to thrive in the feed acidifiers industry.
  • This feed acidifiers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Precision Fermentation Market Opportunity and Consumer Attitudes Measured in Hallmark Study from The Hartman Group

Retrieved on: 
Tuesday, March 7, 2023

Among these, younger consumers expressed the most enthusiasm for new technologies like precision fermentation and want to support companies that align with their own values around the environment and animal welfare.

Key Points: 
  • Among these, younger consumers expressed the most enthusiasm for new technologies like precision fermentation and want to support companies that align with their own values around the environment and animal welfare.
  • “We are excited to partner with The Hartman Group on this research to help us identify where consumers stand in relation to transformative food technologies like precision fermentation.
  • Millennials and Gen Z are the most eager to be early adopters of food innovation, including precision fermentation.
  • Earlier this month, Perfect Day and eight other precision fermentation companies launched the Precision Fermentation Alliance , a new industry group to help build awareness and understanding of precision fermentation technology and its benefits for governments, businesses, manufacturers, and the greater public.

Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering

Retrieved on: 
Tuesday, February 28, 2023

SAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that reproductive telehealth leader SimpleHealth now offers Phexxi® (lactic acid, citric acid and potassium bitartrate), the first and only hormone-free vaginal gel approved by the FDA for contraception.

Key Points: 
  • "This partnership with SimpleHealth will increase awareness of Phexxi and provide access to the only non-hormonal birth control women use on demand," said Saundra Pelletier, Chief Executive Officer of Evofem.
  • "This beneficial alliance "meets" women where they are and delivers on our strategy to expand access to Phexxi."
  • We are proud to offer Phexxi to meet the needs of the many women who want or need a non-hormonal birth control method," said Carrie Siu Butt, Chief Executive Officer of SimpleHealth.
  • The SimpleHealth offering includes contraceptive counseling, resources, and education about women's health as well as online prescriptions, automatic refills and free home delivery of more than 120 brand name and generic products including hormonal birth control – pill, patch or ring – and now hormone-free Phexxi contraceptive vaginal gel.

Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi

Retrieved on: 
Monday, February 27, 2023

SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that two additional U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

Key Points: 
  • SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that two additional U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
  • "The Orange Book listing of these two patents covering Phexxi's composition of matter and its method of use in contraception is an important step in further strengthening our patent portfolio," said Evofem Biosciences CEO Saundra Pelletier.
  • 11,337,989 (the '989 patent) covers contraception using the L-Lactic Acid Phexxi formulation.
  • The '989 patent was issued by the U.S. Patent and Trademark Office (USPTO) on May 24, 2022 and is expected to expire in March 2033.

Global Fermentation Chemicals Market Report 2022 to 2030: Strong Demand for Fermentation Chemicals from the Pharmaceutical Industry is Propelling Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, February 27, 2023

Fermentation chemicals are used to initiate the chemical reactions in synthesize of various chemicals.

Key Points: 
  • Fermentation chemicals are used to initiate the chemical reactions in synthesize of various chemicals.
  • Fermentation chemicals are used to catalyze or initiate the chemical process of fermentation in various products.
  • Moreover, strong demand for fermentation chemicals from the pharmaceutical industry is propelling market growth.
  • Fermentation chemicals are widely used as a preservatives and additives across food &beverage industry, which is expected to offer potential growth opportunities in the near future.